Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer

Kishan J. Pandya; Anuradha R. Thummala; Jennifer J. Griggs; Joseph D. Rosenblatt; Deepak M. Sahasrabudhe; Thomas J. Guttuso; Gary R. Morrow; Joseph A. Roscoe

doi:10.1023/B:BREA.0000010676.54597.22

Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer

Kishan J. Pandya
, Anuradha R. Thummala
, Jennifer J. Griggs
, Joseph D. Rosenblatt
, Deepak M. Sahasrabudhe
, Thomas J. Guttuso
, Gary R. Morrow
, Joseph A. Roscoe

Neurology

University of Rochester
Arvind B. Shah, MD, Inc.
University of Miami

Research output: Contribution to journal › Article › peer-review

38 Scopus citations

Abstract

In this pilot study, 22 women with breast cancer on tamoxifen therapy with at least two hot flashes a day took oral gabapentin at 300 mg three times a day for 4 weeks. The 16 women who completed the study had a mean decrease in hot flash duration of 73.6% (P = 0.027), frequency of 44.2% (P < 0.001), and severity of 52.6% (P < 0.001), with a complete response in 8/16 women. Side effects reported by four women who did not complete 4 weeks of the study were nausea (1/4), rash (1/4) and excessive sleepiness (3/4). Two additional patients did not provide complete data. Gabapentin is a promising new agent in the treatment of tamoxifen induced hot flashes, and should be studied further.

Original language	English
Pages (from-to)	87-89
Number of pages	3
Journal	Breast Cancer Research and Treatment
Volume	83
Issue number	1
DOIs	https://doi.org/10.1023/B:BREA.0000010676.54597.22
State	Published - Jan 2004

Keywords

Breast cancer
Gabapentin
Hot flashes
Tamoxifen

Access to Document

10.1023/B:BREA.0000010676.54597.22

Cite this

@article{bd600c5a054b4c86b16483ac3452b6b2,

title = "Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer",

abstract = "In this pilot study, 22 women with breast cancer on tamoxifen therapy with at least two hot flashes a day took oral gabapentin at 300 mg three times a day for 4 weeks. The 16 women who completed the study had a mean decrease in hot flash duration of 73.6\% (P = 0.027), frequency of 44.2\% (P < 0.001), and severity of 52.6\% (P < 0.001), with a complete response in 8/16 women. Side effects reported by four women who did not complete 4 weeks of the study were nausea (1/4), rash (1/4) and excessive sleepiness (3/4). Two additional patients did not provide complete data. Gabapentin is a promising new agent in the treatment of tamoxifen induced hot flashes, and should be studied further.",

keywords = "Breast cancer, Gabapentin, Hot flashes, Tamoxifen",

author = "Pandya, \{Kishan J.\} and Thummala, \{Anuradha R.\} and Griggs, \{Jennifer J.\} and Rosenblatt, \{Joseph D.\} and Sahasrabudhe, \{Deepak M.\} and Guttuso, \{Thomas J.\} and Morrow, \{Gary R.\} and Roscoe, \{Joseph A.\}",

year = "2004",

month = jan,

doi = "10.1023/B:BREA.0000010676.54597.22",

language = "English",

volume = "83",

pages = "87--89",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer

AU - Pandya, Kishan J.

AU - Thummala, Anuradha R.

AU - Griggs, Jennifer J.

AU - Rosenblatt, Joseph D.

AU - Sahasrabudhe, Deepak M.

AU - Guttuso, Thomas J.

AU - Morrow, Gary R.

AU - Roscoe, Joseph A.

PY - 2004/1

Y1 - 2004/1

N2 - In this pilot study, 22 women with breast cancer on tamoxifen therapy with at least two hot flashes a day took oral gabapentin at 300 mg three times a day for 4 weeks. The 16 women who completed the study had a mean decrease in hot flash duration of 73.6% (P = 0.027), frequency of 44.2% (P < 0.001), and severity of 52.6% (P < 0.001), with a complete response in 8/16 women. Side effects reported by four women who did not complete 4 weeks of the study were nausea (1/4), rash (1/4) and excessive sleepiness (3/4). Two additional patients did not provide complete data. Gabapentin is a promising new agent in the treatment of tamoxifen induced hot flashes, and should be studied further.

AB - In this pilot study, 22 women with breast cancer on tamoxifen therapy with at least two hot flashes a day took oral gabapentin at 300 mg three times a day for 4 weeks. The 16 women who completed the study had a mean decrease in hot flash duration of 73.6% (P = 0.027), frequency of 44.2% (P < 0.001), and severity of 52.6% (P < 0.001), with a complete response in 8/16 women. Side effects reported by four women who did not complete 4 weeks of the study were nausea (1/4), rash (1/4) and excessive sleepiness (3/4). Two additional patients did not provide complete data. Gabapentin is a promising new agent in the treatment of tamoxifen induced hot flashes, and should be studied further.

KW - Breast cancer

KW - Gabapentin

KW - Hot flashes

KW - Tamoxifen

UR - https://www.scopus.com/pages/publications/0942301252

U2 - 10.1023/B:BREA.0000010676.54597.22

DO - 10.1023/B:BREA.0000010676.54597.22

M3 - Article

C2 - 14997058

AN - SCOPUS:0942301252

SN - 0167-6806

VL - 83

SP - 87

EP - 89

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 1

ER -

Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this